Maxim raised the firm’s price target on Nephros (NEPH) to $6 from $4.50 and keeps a Buy rating on the shares. The company’s Q2 results saw revenue, gross margins, and earnings all above consensus estimates, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEPH: